Follicular thyroid cancer is a treatable form of cancer arising in the cells that produce thyroid hormones. While it accounts for only a small portion of all thyroid cancers, understanding the treatment options—from surgical removal to newer therapies being tested in clinical trials—can help patients navigate their care journey with confidence and hope.

Understanding Your Treatment Path

When a person receives a diagnosis of follicular thyroid cancer, the first questions that often arise concern treatment options and what lies ahead. The good news is that this type of cancer is highly treatable, with cure rates approaching 95% for many patients. Treatment decisions depend on several key factors: the size of the cancer, whether it has spread beyond the thyroid gland, the patient’s age and overall health, and individual preferences about care.^[1][2]

The main goals of treatment include removing all cancer tissue from the body, preventing the cancer from coming back, and maintaining or restoring the body’s normal functions. Because follicular thyroid cancer tends to spread through blood vessels rather than lymph nodes, doctors pay special attention to checking for distant spread to organs like the lungs or bones. Age plays an important role in prognosis—patients younger than 55 years typically have more favorable outcomes than older patients.^[2][3]

Medical societies and expert groups have developed treatment guidelines based on decades of research and clinical experience. These recommendations are continuously updated as new evidence emerges from studies around the world. Additionally, researchers are actively investigating new treatment approaches through clinical trials, offering hope for even better outcomes in the future.

Standard Treatment Approaches

Surgical Treatment: The Foundation of Care

Surgery remains the cornerstone of treatment for follicular thyroid cancer. The type of operation performed depends on the extent of disease and specific characteristics of the cancer. In many cases, the diagnosis of follicular thyroid cancer cannot be confirmed until after surgery, when a pathologist—a doctor who examines tissue under a microscope—reviews the removed tissue for signs of invasion into the thyroid capsule or blood vessels.^[7][11]

A lobectomy, which removes only one lobe (half) of the thyroid gland, may be performed initially when a follicular tumor is suspected but not yet confirmed to be cancer. This operation is generally considered for smaller tumors confined to one side of the thyroid. However, if the pathology report confirms follicular cancer, a second operation called a completion thyroidectomy may be necessary to remove the remaining thyroid tissue.^[12][17]

A total thyroidectomy—removal of the entire thyroid gland—is often the preferred initial approach for follicular thyroid cancer, especially when the tumor is larger than 1 centimeter, shows signs of invasion, or when there is evidence of spread beyond the thyroid. During this operation, the surgeon carefully works around important structures in the neck, including the four tiny parathyroid glands that control calcium levels in the blood, and the recurrent laryngeal nerves that control the voice box.^[8][11]

If imaging tests or biopsies show that the cancer has spread to lymph nodes in the neck, the surgeon will perform a neck dissection to remove these affected nodes. This is less common with follicular thyroid cancer than with papillary thyroid cancer—lymph node spread occurs in only about 8 to 12% of follicular cases—but it is still an important part of treatment when present.^[2][6]

Radioactive Iodine Therapy

After surgery, many patients receive radioactive iodine therapy, also called RAI therapy or radioiodine treatment. This treatment takes advantage of a unique property of thyroid cells: they absorb iodine from the bloodstream. When a patient swallows a capsule or liquid containing radioactive iodine (I-131), any remaining thyroid tissue or thyroid cancer cells absorb this radioactive substance, which then destroys them from the inside.^[12][13]

RAI therapy is particularly effective for follicular thyroid cancer because these cells typically retain the ability to concentrate iodine. Before treatment, doctors perform a radioactive iodine uptake test to confirm that the cancer cells will absorb the iodine. The decision to use RAI therapy depends on several factors, including the size of the original tumor, whether it invaded blood vessels, and whether there is evidence of spread to distant sites like the lungs or bones.^[12][19]

The treatment is typically given about 4 to 6 weeks after surgery, allowing time for the body to heal and for thyroid hormone levels to change in a way that makes cancer cells more likely to absorb the radioactive iodine. Patients may need to follow a special low-iodine diet before treatment and stay away from pregnant women and young children for a few days afterward due to the radiation.^[8]

Thyroid Hormone Replacement and Suppression Therapy

After a total thyroidectomy, patients must take synthetic thyroid hormone medication for the rest of their lives. The most commonly prescribed medication is levothyroxine (also called L-T4), which replaces the hormones the thyroid gland normally produces. The typical dose is between 2.5 and 3.5 micrograms per kilogram of body weight per day.^[8][18]

This medication serves two important purposes. First, it provides the thyroid hormones the body needs for normal metabolism, heart function, and temperature regulation. Second, at slightly higher doses, it suppresses production of thyroid-stimulating hormone (TSH) by the pituitary gland. TSH can stimulate any remaining thyroid cancer cells to grow, so keeping TSH levels low—typically between 0.1 and 0.5 milli-international units per liter—may help prevent cancer recurrence.^[8][19]

Doctors monitor thyroid hormone levels through regular blood tests and adjust the medication dose as needed. This hormone therapy is generally well-tolerated, though taking too much can cause symptoms similar to an overactive thyroid, such as rapid heartbeat, nervousness, or bone loss over time.

External Beam Radiation Therapy

While less commonly used than surgery or radioactive iodine, external beam radiation therapy plays an important role in specific situations. This treatment uses high-energy rays directed at the cancer from outside the body. It may be recommended when all of the cancer could not be removed during surgery, when the cancer has invaded nearby structures like the windpipe or esophagus, or when cancer recurs in the neck and no longer responds to radioactive iodine.^[8][12]

Treatment typically involves daily sessions over several weeks, with total doses ranging from 6,000 to 6,500 centigrays. The radiation oncologist carefully plans the treatment to target cancer cells while minimizing exposure to surrounding healthy tissues. Common side effects include fatigue, skin irritation in the treated area, dry mouth, and difficulty swallowing, though many of these effects are temporary.^[8]

Innovative Treatments in Clinical Trials

For patients whose cancer does not respond to standard treatments—particularly those with cancer that has spread to distant organs and no longer absorbs radioactive iodine—researchers are investigating new therapeutic approaches through clinical trials. These studies are testing medications that target specific molecular pathways involved in cancer growth and spread.

Targeted Therapy: Tyrosine Kinase Inhibitors

Targeted therapy represents a newer approach that focuses on specific molecules and pathways essential for cancer cell survival and growth. For follicular thyroid cancer that has become resistant to radioactive iodine—called radioiodine-refractory disease—several tyrosine kinase inhibitors have shown promise in clinical trials.^[6][8]

These medications work by blocking signals that tell cancer cells to grow and divide. They may also interfere with the formation of new blood vessels that tumors need to survive. While specific drug names and trial details were not extensively covered in the available sources, these agents are being tested primarily in Phase II and Phase III clinical trials, which evaluate both effectiveness and how they compare to existing treatments.

Clinical trials for advanced follicular thyroid cancer are conducted at major cancer centers in the United States, Europe, and other regions. Patients with symptomatic disease that continues to progress despite standard treatments may be eligible to participate. These trials carefully monitor both beneficial effects—such as tumor shrinkage or stabilization—and potential side effects.^[6][8]

Understanding Clinical Trial Phases

Phase I trials focus primarily on safety, determining the appropriate dose of a new medication and identifying potential side effects in a small group of patients. Phase II trials expand to a larger group to assess whether the treatment actually works against the cancer while continuing to monitor safety. Phase III trials compare the new treatment directly with standard therapy to determine if it offers advantages in terms of effectiveness, quality of life, or reduced side effects.^[8]

For follicular thyroid cancer specifically, many clinical trials focus on patients with metastatic disease—cancer that has spread to lungs, bones, or other distant sites. Preliminary results from some studies have shown that targeted therapies can slow tumor growth and improve quality of life for patients with bone metastases, even when these cancers no longer respond to radioactive iodine.^[6]

Patients interested in clinical trials should discuss this option with their healthcare team. Oncologists can help determine whether a patient meets eligibility criteria for available studies and explain the potential benefits and risks of participation.

Most common treatment methods

• Surgery
  • Lobectomy removes one lobe of the thyroid gland and may be used as an initial procedure when follicular cancer is suspected.
  • Completion thyroidectomy removes the remaining thyroid tissue after lobectomy confirms cancer.
  • Total thyroidectomy removes the entire thyroid gland and is commonly used for larger tumors or when there is invasion beyond the thyroid.
  • Neck dissection removes affected lymph nodes when cancer has spread to these structures.
• Radioactive Iodine Therapy
  • Uses radioactive iodine (I-131) that is absorbed by thyroid cancer cells, destroying them from within.
  • Administered as a pill or liquid approximately 4 to 6 weeks after surgery.
  • Particularly effective for follicular thyroid cancer because these cells typically retain the ability to concentrate iodine.
  • Used to treat remaining cancer cells after surgery or cancer that has spread to distant organs.
• Thyroid Hormone Replacement Therapy
  • Levothyroxine (L-T4) replaces hormones normally produced by the thyroid gland.
  • Required for life after total thyroidectomy at doses of 2.5-3.5 micrograms per kilogram daily.
  • Also suppresses thyroid-stimulating hormone (TSH) to prevent stimulation of any remaining cancer cells.
  • Requires regular blood tests to monitor hormone levels and adjust dosing.
• External Beam Radiation Therapy
  • Uses high-energy rays directed at cancer from outside the body.
  • Recommended when cancer cannot be completely removed surgically or has invaded nearby structures.
  • May be used for recurrent cancer that no longer responds to radioactive iodine.
  • Typical treatment doses range from 6,000 to 6,500 centigrays delivered over several weeks.
• Targeted Therapy
  • Tyrosine kinase inhibitors block specific molecular signals that cancer cells need to grow.
  • Being tested in clinical trials for radioiodine-refractory follicular thyroid cancer.
  • May slow tumor growth and improve quality of life in patients with metastatic disease.
  • Available primarily through clinical trials at specialized cancer centers.

Living After Treatment

Following successful treatment, patients enter a phase of long-term monitoring to ensure the cancer has not returned. This typically involves regular visits with an endocrinologist or oncologist, blood tests to measure thyroid hormone levels and thyroglobulin—a protein produced by thyroid cells that can serve as a tumor marker—and periodic imaging studies such as ultrasound or radioactive iodine scans.^[7][14]

The frequency of follow-up visits and tests depends on the initial stage of cancer and the risk of recurrence. Patients at low risk may need less frequent monitoring, while those with more advanced disease or high-risk features require more intensive surveillance. Even though follicular thyroid cancer can recur many years after initial treatment, the 10-year recurrence rate is generally between 20 and 30%, primarily affecting older patients and those with larger original tumors.^[8][15]

Most patients with follicular thyroid cancer can expect excellent long-term survival. The 5-year survival rate for localized disease approaches 100%, while even patients with regional spread to lymph nodes have a 98% 5-year survival rate. For those with distant metastases at diagnosis, the 5-year survival rate is 63%, which remains favorable compared to many other cancer types.^[15][20]

Quality of life after treatment is generally good, though patients must commit to lifelong thyroid hormone replacement therapy. Some individuals experience side effects from their medication if the dose is not properly balanced, and regular monitoring helps optimize treatment. Patients should maintain open communication with their healthcare team about any symptoms or concerns that arise during follow-up.